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SARS-CoV-2 has emerged as a human pathogen, causing clinical signs, from fever to
pneumonia—COVID-19—but may remain mild or asymptomatic. To understand the con-
tinuing spread of the virus, to detect those who are and were infected, and to follow the
immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and
immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies rec-
ognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a
period of 6 months following COVID-19 onset. We report the detailed setup to monitor
the humoral immune response from over 300 COVID-19 hospital patients and health-
care workers, 2500 University staff, and 198 post-COVID-19 volunteers. Anti-SARS-CoV-2
antibody responses follow a classic pattern with a rapid increase within the first three
weeks after symptoms. Although titres reduce subsequently, the ability to detect anti-
SARS-CoV-2 IgG antibodies remained robust with confirmed neutralization activity for
up to 6 months in a large proportion of previously virus-positive screened subjects. Our
work provides detailed information for the assays used, facilitating further and longitudi-
nal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued
level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.
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Introduction
SARS-CoV-2 infection causes a wide variety of disease symptoms,
from fever, asthenia, or myalgia, to pneumonia and in most severe
cases acute respiratory distress syndrome referred to as COVID-
19. Yet, a large amount of SARS-CoV-2 infected patients remains
asymptomatic. SARS-CoV-2 rapidly spread around the world and
was declared a global pandemic in March 2020. It remains a con-
tinuing threat to health and socio-economic well-being. Despite
the global number of infections reaching tens of millions, includ-
ing almost one million fatalities, due to mitigation measures,
the overall infection rate is relatively low with local infection
hotspots. Although scientific progress is rapid, there remains a
pressing need to understand the immune response that follows
SARS-CoV-2 infection, including its role during disease and espe-
cially its potential long-term protective effects.
A prime immune target during coronavirus infections is the
Spike (S) protein, closely associated with and targeted by neu-
tralizing antibody responses and protective immunity, in contrast
to most other viral proteins [1–4]. The S protein is responsible
for the interaction of SARS-CoV-2 with the host cells via bind-
ing ACE2 [5–7]. It can be divided into two regions, S1 and
S2. The extra-viral S1 region contains within its second domain
the receptor-binding domain (RBD) [8]. The SARS-CoV-2 RBD
sequence shows limited homology with seasonal coronaviruses or
EMC/2012, the cause of the Middle East respiratory syndrome
(MERS). In contrast, SARS-CoV-2 RBD shares 73% of its sequence
with the RBD of SARS [3].
Attempts to curtail and control the SARS-CoV-2 virus rely on
increasing inter-personal distance, including the closure of much
social and economic activity, as well as testing for acute infection
and personal hygiene measures. This was implemented early dur-
ing the outbreak, with the University of Lisbon closing after March
13th, 10 days after the first recorded cases in Portugal. How-
ever, during the subsequent transition phase, restrictions have
steadily been lifted. The gradual return to social and economic
activity requires active surveillance to determine local outbreaks,
contact tracing, and quarantine. In addition, those most vulnera-
ble to COVID-19 will need to remain under enhanced protection.
Important information is how protective immunity develops in the
population at large and in specific groups such as healthcare pro-
fessionals. A thorough assessment of the duration of protective
immunity is critical to determine the measures that need to be
taken to prevent and handle future waves of SARS-CoV-2. Such
information will need to be gathered widely, in different locations
around the world, reflecting local conditions, such as containment
measures and their timing. The data obtained will need to be
accurate and the methods used transparent and reproducible to
enable comparisons between locations and countries. The recent
SARS-CoV-2 outbreak brings limitations with respect to exposure
time but also gives us the opportunity to acquire real-time data
and develop reliable longitudinal follow-up studies.
To determine the cumulative rate of infection in communi-
ties and gaining insight into the potential protection against re-
infection, serological assays are critical. Depending on the aims of
the study, the setup of such assays can be used for the detection
of exposure to SARS-CoV-2 as well as gaining insights into neu-
tralization activity, since antibody titers for both the S protein and
RBD have been shown to correlate well with neutralizing activity
[3, 9–11]. We describe the detailed setup and versatility of a sero-
conversion assay to determine humoral immunity to SARS-CoV-2
that was used for screening hospital patients, healthy post-COVID-
19 volunteers, and staff of the University of Lisbon. We report that
in the acute phase men produce more antibodies than women do,
but levels equilibrate during the resolution phase and are simi-
lar between the sexes in the months after SARS-CoV-2 infection.
We show that antibodies against SARS-CoV-2 Spike and its RBD
domain are readily detectable in the majority of cases, including in
patients receiving immune suppressive or anti-retroviral therapy.
In line with a classic immune response, SARS-CoV-2 antibodies in
the blood peak around week 3 post-infection, and although anti-
body titers reduce, IgG antibodies remain detectable and show




The gold standard for antibody detection remains the ELISA,
offering high flexibility and sensitivity, but limited scalability
[11]. SARS-CoV-2 Spike is a prominent immunogenic antigen and
its RBD is least conserved compared with other coronaviruses.
Hence, the use of Spike and its RBD quickly became the focus of
seroconversion assays. We chose for the present study the assay
developed by Florian Krammer and his laboratory, a format that
received FDA emergency approval in April 2020 and is described
in detail [12].
Human sera pose a biological hazard to laboratory workers
and can potentially contain not only SARS-CoV-2, but also other
infectious viruses. Therefore, all ELISA steps were performed at
biosafety level (BSL) 2, with BSL3 personal protective equipment.
Inactivation procedures are recommended but can have uncertain
effects on the accuracy of serological testing [13]. We tested three
common procedures: (a) 1 h heat inactivation at 56°C, or (b) the
addition of a non-ionic surfactant (0.1% Triton X-100), or (c) the
combination of both, in comparison to neat serum. Serial dilutions
of two chosen SARS-CoV-2 PCR-positive serum samples showed
IgG detection following all three inactivation methods and were
indiscriminate from untreated controls (Fig. 1A).
The S protein has a trimeric structure, while the in vitro
expression of RBD results in the generation of monomeric and
dimeric protein. However, when we tested the ability of RBD
mono- and dimeric protein for antibody binding, both performed
similar and comparable to the total protein fraction (Figure 1B).
Additional parameters affecting the performance of ELISA assays,
such as the coating time (o/n – 1 week at 4°C), serum incuba-
tion time and temperature, as well as the amount of tetramethyl-
benzidine (TMB) substrate and the development time (adjusted
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Figure 1. SARS-CoV-2 ELISA setup. SARS-CoV-2 IgG antibody detec-
tion in serum samples from SARS-CoV-2 PCR-positive subjects or pre-
COVID-19 controls using Immulon 4HBX 96-well plates coatedwith RBD
protein for ELISA. Absorbance (optical density, OD) was evaluated at 450
nm. (A) Three serum samples, pre-COVID-19 control,medium, and high
titer were treated by the indicated methods to inactivate virus parti-
cles. (B) Isolated RBD monomer, RBD dimer, pooled RBD and Spike pro-
tein were used for coating at the same conditions, and four COVID-19
serum samples (colored) were tested versus four pre-COVID-19 (open
symbols). (C and D) 96-well plate was coated with (C) RBD or (D) Spike
protein at indicated concentrations and three COVID-19 (colored) and
pre-COVID-19 (black) sera were tested. (E) Secondary antibody dilution
titration anti-IgG, at indicated dilution on 96-well plate coated with 2
μg/ml RBD protein for three sera. (F) Quality control (QC) and sample
serum serial dilution. QC sample is a mix of the serum samples tested
from four healthcare workers (S1–S4). Dashed line indicates blank val-
ues. Data show individual sample values.
to 10 min) were optimized (Supporting Information Fig. S1A,
data not shown). Coated plates were stable for a week and incu-
bation of 1 or 2 h at room temperature or 37°C was indistin-
guishable. To ensure that the ELISAs runs at non-saturating con-
ditions, we performed a full titration of the capture antigens
(from 0.125 to 10 μg/mL) and the secondary antibodies (1:5000–
1:100 000) used for antibody detection. SARS-CoV-2 proteins
were titrated and assessed using individual patient sera (high,
medium, and low titers). Simultaneously, the secondary antibod-
ies were titrated, such as anti-IgG, but also anti-IgM, anti-IgA, and
anti-total Ig, whereby OD of 2.0 was used as an upper limit to
avoid saturation of the assay (Fig. 1C–E; Supporting Information
Fig. S1B–G).
In order to prepare for diagnostic use, the generation of
quality control (QC) serum is critical to validate each assay run.
Sera from exposed patients is most desirable as it will contain
antibodies with a range of avidities and isotypes, providing more
stable binding properties. However, sufficient volume needs to
be obtained to ensure that there is enough material to complete
the ELISA validation process and the study or series of studies to
be undertaken. Sera from four SARS-CoV-2 exposed but healthy
volunteers were assessed and pooled to serve as quality control
for subsequent assays (Fig. 1F). Ultimately, antibody signals
should diminish in a dose-dependent way using serial dilutions of
the sera, enabling the accurate determination of antibody titers
(Supporting Information Fig. S1H).
Seroconversion assay validation
We used 100 pre-COVID-19 sera from healthy volunteers collected
between October 2012 and November 2017 as negative controls
(Table 1). Furthermore, we obtained 19 sera from PCR positive
hospital healthcare workers with mainly mild symptoms, just over
30 days since the first symptoms and the positive SARS-CoV-2
PCR result (Table 2). Seroconversion was detected in the sera of
all SARS-CoV-2 PCR-positive patients using the RBD part of SARS-
CoV-2 S antigen and 18 of 19 using the full-length SARS-CoV-2 S
protein by probing for IgG (Figure 2A). Receiver operating char-
acteristic (ROC) curve determined sensitivity and specificity and
the assay´s cutoff at 0.4171 and 0.4816 for RBD and S protein,
respectively, corresponding to 100% specificity and 99% sensitiv-
ity for RBD and 94.74% specificity and 98% sensitivity for Spike
in this initial analysis (Fig. 2B and C and Table 3).
In order to increase pre-COVID-19 sample size and reflect a
broader spectrum of the population, we obtained 61 samples of
individuals with food allergies and 20 samples from individu-
als with bee and wasp allergies, because these contain increased
levels of antibodies [14]. Serum from allergic subjects increased
the observed background on both RBD and Spike proteins (Fig-
ure 2D). Of importance, increased reactivity to one protein was
often not observed on the second SARS-CoV-2 protein (Fig-
ure 2E), substantiating the two-step process of screening for RBD
and subsequently, those sera found positive for Spike [12].
Seroconversion screening of COVID-19 hospitalized
patients
We subsequently analyzed 307 samples from hospitalized patients
who tested positive for SARS-CoV-2 by PCR for the presence of
anti-SARS-CoV-2 IgG. Samples were acquired between April 6
and August 12, 2020 and at different times after the development
of COVID-19 symptoms. The patients demonstrated a variety of
symptoms and underlying medical conditions (Table 1). Sero-
conversion screening resulted in varied OD measurements when
including all samples assessed (Fig. 3A). Taking into account the
number of days taken by adaptive cellular immunity to be initi-
ated, we further separated the samples into 14 days post-onset,
excluding those that were asymptomatic, which revealed a robust
seroconversion in 73 of 73 (100%) samples on RBD and 71 of 73
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Table 1. Demographics of patient participants, disease severity categories and symptoms, underlying conditions, and medication
Clinical data (%, n) COVID-19 COVID-19 (<Day7) Pre-COVID-19
Pre-COVID-19
Allergies Asymptomatic
Age (years) 63.23 (20-93) 68.77 (20-98) 54.73 (20-88) 30.59 (2-71) 62.85 (22-98)
Male 48% 91 54% 42 49% 49 51% 41 55% 22
Female 52% 98 46% 36 51% 51 49% 40 45% 18










SARS-CoV-2 PCR+ 100% 100% N/A N/A 100%
Seroconversion (Spike) 82% (155/189) 50% (39/78) 2.0% (2/100) 6.2% (5/81) 50% (20/40)
Seroconversion (RBD) 84% (159/189) 51% (40/78) 0.0% (0/100) 7.4% (6/81) 50% (20/40)
Disease Severity
Mild 18% 31 16% 13 N/A N/A 0%
Moderate 73% 127 73% 60 N/A N/A 0%
Severe 10% 17 11% 9 N/A N/A 0%
Symptoms
Cough 60% 105 61% 50 N/A N/A N/A
Myalgia 30% 53 18% 15 N/A N/A N/A
Fever 60% 105 59% 48 N/A N/A N/A
Anosmia 9% 15 2% 2 N/A N/A N/A
Dyspnea 35% 62 49% 40 N/A N/A N/A
Diarrhea 13% 23 12% 10 N/A N/A N/A
Odynophagia 1% 1 0% 0 N/A N/A N/A
Hypogeusia 3% 6 0% 0 N/A N/A N/A
Headache 19% 33 10% 8 N/A N/A N/A
Rhinorrhea 1% 1 0% 0 N/A N/A N/A
Asthenia 33% 57 27% 0 N/A N/A N/A
Days Post Symptom
onset at collection
15.53 (3-52) 3.88 (1-7) N/A N/A N/A
PCR+ day to serum
collection
12.07 (1-63) 4.04 (0-15) N/A N/A 10.74 (-1-53)
Underlying conditions
None 21.71% 38 6.10% 5 N/A N/A 22.22% 6
Chronic kidney disease 10.86% 19 17.07% 14 N/A N/A 40.74% 11
Diabetes 25.71% 45 25.61% 21 N/A N/A 33.33% 9
Hypertension 50.29% 88 57.32% 47 N/A N/A 77.78% 21
Heart disease 6.29% 11 17.07% 14 N/A N/A 7.41% 2
Alzheimer 0.00% 0 1.22% 1 N/A N/A 0.00% 0
Cerebrovascular disease 3.43% 6 7.32% 6 N/A N/A 0.00% 0
Dementia/Parkinson 14.29% 25 21.95% 18 N/A N/A 11.11% 3
Asthma 1.14% 2 4.88% 4 N/A N/A 0.00% 0
Cancer 10.29% 18 7.32% 6 N/A N/A 40.74% 11
COPD 2.86% 5 4.88% 4 N/A N/A 0.00% 0
HIV 2.86% 5 4.88% 4 N/A N/A 11.11% 3
SLE 1.14% 2 0.00% 0 N/A N/A 0.00% 0
Medication
None 89.71% 157 85.37% 70 N/A NA 55.56% 15
Midostaurin 0.57% 1 0.00% 0 N/A NA 0.00% 0
Aciclovir 0.57% 1 0.00% 0 N/A NA 0.00% 0
Tacrolimus 2.29% 4 2.44% 2 N/A NA 0.00% 0
Prednisolone 4.57% 8 6.10% 5 N/A NA 0.00% 0
Chemotherapy
(Paclitaxel)
0.00% 0 0.00% 0 N/A NA 7.41% 2
Methotrexate 0.00% 0 1.22% 1 N/A NA 0.00% 0
Raltegravir 0.57% 1 1.22% 1 N/A NA 3.70% 1
Darunavir/Cobicistat 0.57% 1 1.22% 1 N/A NA 3.70% 1
Exemestane 1.14% 2 0.00% 0 N/A NA 0.00% 0
(Continued)
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Table 1. Continued
Clinical data (%, n) COVID-19 COVID-19 (<Day7) Pre-COVID-19
Pre-COVID-19
Allergies Asymptomatic
Azathioprine 1.14% 2 1.22% 1 N/A N/A 0.00% 0
Dexamethasone 0.00% 0 0.00% 0 N/A N/A 3.70% 1
Tamoxifen 0.57% 1 1.22% 1 N/A N/A 0.00% 0
Abacavir 0.57% 1 1.22% 1 N/A N/A 7.41% 2
Lamivudina 0.57% 1 1.22% 1 N/A N/A 7.41% 2
Micofenolate 1.14% 2 1.22% 1 N/A N/A 0.00% 0
Entecavir 0.57% 1 0.00% 0 N/A N/A 0.00% 0
Dolutegravir 0.57% 1 0.00% 0 N/A N/A 7.41% 2
(97.3%) on Spike protein (Fig. 3B). Although antibody responses
take time to mature, around half of the samples obtained in
the first-week post-symptoms showed robust IgG seroconversion
within the first week of symptoms, 40 of 78 (51%) and 39 of 78
(50%) on RBD and Spike, respectively (Fig. 3C). Follow up sam-
ples from 68 patients showed that those who had seroconverted
in the first week of symptoms maintained high levels of IgG 1
week later (27/27, 100%). From all symptomatic subjects, those
who did not have an IgG response within the first week, 30 of 41
(73%) showed a robust response seven days later (days 9-14). The
remaining 11 of 41 (27%) patients had their second sample ana-
Table 2. Demographics of healthcare participants, disease severity
categories, and symptoms
Clinical data (%, n) Healthcare workers
Age (years) 41.84 (25-61)
Male (%) 16% 3
Female (%) 84% 16
Sample collection date 6/4/2020 - 27/5/2020
SARS-CoV-2 PCR+ 100%
Seroconversion (Spike) 94.70% (18/19)


















Days Post Symptom onset
at collection
34.5 (3-55)
PCR+ day to serum
collection
33.05 (13-63)
lyzed in the second week, pre-day 14 after onset of symptoms, still
did not show an IgG response. However, although some patients
did not show an IgG response in the second or even third week
after onset of symptoms, those that were tested again 1 week
later all seroconverted (10/10) (Fig. 3D). From those who did
not seroconvert within week 2 of COVID-19 symptoms (11/41,
27%), some had underlying conditions, such as systemic lupus
erythematosus (SLE) (1), lymphoma (1), chemotherapy (1), or
immunosuppressive medication (3).
Some patients who were SARS-CoV-2 PCR positive within an
average of 8.7 days (-1 - 53) after blood was taken, did not
show any classic COVID-19 symptoms (Table 1). Of these, 20 of
40 (50%) patients showed seroconversion for anti-SARS-CoV-2
IgG (Figure 3E). Since no symptoms were reported, it remained
unclear at what stage of the infection these patients were. Those
who were IgG negative may have been within the first days of
infection, or antibody levels were very low. However, repeated
sampling from several patients seven days later revealed that only
3/11 (27%) patients seroconverted, although OD remained mod-
est, while in six of 11 (55%) anti-SARS-CoV-2 RBD IgG levels
remained below the assay´s cutoff (Figure 3F). This suggests a
limited or much-delayed seroconversion response.
Effect of demographics, immunomodulatory, and
antiviral medication on seroconversion
IgG seroconversion, 14 days after onset of symptoms, was
detected equally well between female and male patients, inde-
pendently of age, and for both RBD and Spike protein (Fig. 4A
and B). Seroconversion detection or the antibody response, since
patients were assayed on average 8.5 days after being SARS-CoV-
2 PCR positive, were reduced or delayed in those asymptomatic
for COVID-19 compared with those experiencing COVID-19 symp-
toms (Fig. 4C). In line with an adaptive immune response taking
several days to develop, the main factor influencing seroconver-
sion was time since the onset of COVID-19 symptoms (Figure 4D).
Within the hospital patient cohort, two groups were of spe-
cial interest, those on immunosuppressive therapy and those
receiving antiviral medication due to infections with either HIV
or hepatitis B virus (HBV) (Table 4). Within the patient cohort
receiving immunosuppressive medication, seven of 29 (24%)
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Figure 2. SARS-CoV-2 ELISA testing. SARS-CoV-2 IgG antibody detection in serum samples from SARS-CoV-2 PCR-positive subjects (colored) or
pre-COVID-19 controls (open) using Immulon 4HBX 96-well plates coated with RBD (circles) or Spike (squared) proteins for ELISA. Absorbance was
evaluated at 450 nm. (A) Serum at 1/50 dilution from 19 SARS-CoV-2 PCR-positive healthcare workers were assessed for anti-SARS-CoV-2 RBD and
Spike IgG and compared with 100 pre-COVID-19 sera. Bars indicate mean ± SD. (B and C) ROC analysis, plotting sensitivity against the specificity
of (B) RBD or (C) Spike samples as shown in (A). D) Serum at 1/50 dilution from pre-COVID-19 cohorts, healthy (100 donors, open symbols), food
allergies (61 donors, dark grey symbols), and bee/wasp allergies (20 donors, light grey symbols), were tested for RBD and Spike protein reactivity.
(E) Example of cross-reactivity on RBD or Spike protein from pre-COVID-19 serum as used in (D). Statistical analysis was performed using Kruskal–
Wallis test with Graphpad Prism software. *p < 0.05, ***p < 0.001. Dashed lines indicate Black, blank values; Red, RBD cutoff; Green, Spike cutoff.
Data show individual sample values.
were asymptomatic for COVID-19. The average seroconversion
rate in both groups was below those seen in the collective patient
cohort or the healthcare workers, at 9/29 (31%) (Table 4).
Within the hospital cohort, we obtained 29 sera from patients
who received immunosuppressive drugs, including 13 of 29
(40%) receiving the glucocorticoids Prednisolone or Dexametha-
sone. Sera of these patients were collected between days 2 and
35 post-COVID-19 symptom onset. In this cohort, all patients
tested SARS-CoV-2 positive by PCR, 20 of 29 (69%) did not sero-
convert (Fig. 4E). Out of these 20, seven (35%) were asymp-
tomatic, and three (15%) were tested within 7 days of symptoms.
In line with required T cell help for isotype switching, three of
five (67%) patients on the calcineurin inhibitor Tacrolimus, which
was combined with Prednisolone did not seroconvert. The use of
corticosteroids had an inhibitory effect on antibody production,
with those patients that seroconverted showing a low signal. The
patient on chemotherapy (Paclitaxel) did not show an anti-SARS-
CoV-2 RBD IgG response. Three (3/29, 10%) patients receiving












0.4171 99.00 94.55- 99.97 100.00 82.35- 100.00 0.4816 98.00 92.96- 99.76 94.74 73.97- 99.87
0.5532 100.00 96.38- 100.00 100.00 82.35- 100.00 0.6302 99.00 99.55- 99.97 94.74 73.97- 99.87
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Figure 3. Seroconversion in hospitalized patients. SARS-CoV-2 IgG antibody detection in serum samples from SARS-CoV-2 PCR-positive hospital
patients (colored) or pre-COVID-19 controls (open) using Immulon 4HBX 96-well plates coated with RBD (circles) or Spike (squared) proteins for
ELISA. Absorbance was evaluated at 450 nm. (A) Overview of all over 300 SARS-CoV-2 PCR-positive tested subjects from Hospital Santa Maria
and accumulated 181 pre-COVID-19 controls. (B) Selected samples presented in (A) post-day 14 of the initial reported COVID-19 symptoms (n = 73
COVID-19 donors,n= 100 pre-COVID-19 healthy controls). (C) Selected samples presented in (A) pre-day 7 of the initial reported COVID-19 symptoms
(n = 78 COVID-19 donors, n = 100 pre-COVID-19 healthy controls). (D) Longitudinal follow-up of patients sampled at the indicated week of COVID-19
symptom onset and re-sampling 7 days later (n = 76 COVID-19 donors). Blue indicates continued high signal, Green those that seroconverted at
the second sampling in week 2, Orange those that seroconverted at the second sampling past week 2, Red those in which no seroconversion was
detected in first and second sampling. (E) Selected samples presented in (A) without reported COVID-19 symptoms (n = 40 COVID-19 donors, n = 100
pre-COVID-19 healthy controls). (F) Longitudinal follow-up of asymptomatic patients sampled in the first week of COVID-19 symptom onset and
re-sampling 7 days later, colors as used as in (D) (n = 10 donors). Dashed lines indicate Black, blank values; Red, RBD cutoff; Green, Spike cutoff.
Data show individual sample values, bars indicate mean ± SD.
immunomodulatory drugs showed a similar anti-SARS-CoV-2 IgG
response compared with patients without such medication (days 5
to 13). Two of these received either Prednisolone or Methotrexate.
Although the number of patients tested was modest, these find-
ings indicate that immunosuppressive medications inhibit sero-
conversion upon SARS-CoV-2 infection.
Twelve samples were from patients who previously contracted
HIV1 or HIV2 and were treated with antiretroviral therapy (Ral-
tegravir, Darunavir/Cobicistat, Lamivudine, and Dolutegravir)
and one with HBV receiving Entecavir. All patients were male
and SARS-CoV-2 seroconversion was analyzed within 11 days
of symptom onset. Most patients (9/12, 75%) seroconverted
(Fig. 4F). Of the remaining three HIV patients, two were asymp-
tomatic and one was an early sample taken only 3 days after
COVID-19 symptoms. These results suggest that anti-retroviral
medication does not interfere with SARS-CoV-2 seroconversion.
Large seroconversion screen shows limited
SARS-CoV-2 exposure
The University of Lisbon decided to close for all non-essential
work early during the COVID-19 outbreak, starting from midnight
March 13. Since the initial outbreak, reported infection levels
in Portugal have remained modest compared with nearby Euro-
pean countries, with 5200 cases per million of the population
reported (Johns Hopkins, Worldometer, August 2020). To deter-
mine the seroprevalence in University staff, we screened 2571
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Figure 4. Seroconversion in subgroups and time. SARS-CoV-2 IgG anti-
body detection in serum samples from SARS-CoV-2 PCR-positive hos-
pital patients or pre-COVID-19 controls using Immulon 4HBX 96-well
plates coated with RBD (circles) or Spike (squared) proteins for ELISA.
Absorbance was evaluated at 450 nm. (A and B) IgG OD signals were
plotted of (A) female (n = 42) and male (n = 28) or (B) by age at the time
of blood sampling, of those subjects 14-days post first COVID-19 symp-
toms. Red line marks the mean. (C and D) IgG OD signals of all subjects
were plotted by (C) severity of symptoms or (D) over time since the day
of first symptoms. (E and F) Hospital patients receiving (E) immunomod-
ulatory medication (orange, n = 31) or (F) antiviral medication (pur-
ple, n = 12) who tested SARS-CoV-2 PCR-positive were assessed for IgG
antibodies and compared with pre-COVID-19 controls (open symbols,
n = 100). Statistical analysis was performed using Kruskal–Wallis test
using Graphpad Prism software. *p < 0.05, **p < 0.01, ***p < 0.001. Data
show individual sample values, bars indicate mean ± SD.
employees, across all divisions, with serum obtained between May
13 and July 10, 2020. As mentioned, our assay is based on Stadl-
bauer et al. [12] that received emergency FDA approval utilizing
a two-step method. With the expectation of a low infection preva-
lence, we first screened staff in a single dilution using the setup
as depicted in Figure 5A. We detected 68 samples with an OD
above the cut off value of 0.41 (2.6%) (Fig. 5B). These samples
were subsequently reassessed, using both RBD and Spike protein
as well as two serum dilutions, 1/50 and 1/150, as depicted in
Figure 5C. Of the 68 tested samples, 38 (56%) were confirmed
positive during the second assay (Fig. 5D and E), resulting in an
infection prevalence of 1.5%. Samples with an intermediate signal
for RBD, often just above the cutoff, frequently failed the second
assay on Spike or even RBD (Fig. 5E and F) and some samples
with a robust RBD signal did not respond to Spike protein at all.
As previously observed (Fig. 2), signals between RBD and Spike
protein were often comparable, with only a few samples show-
ing a stronger response against Spike. Samples providing a robust
signal for RBD often responded similarly with Spike (Fig. 5G). To
ensure ODs between plates are comparable, the assays inter-plate
variation was determined using two dilutions of a QC serum sam-
ple or monoclonal antibody (QChi and QClo) run in each plate.
Although day-to-day plate variability is present, this is of very
modest amplitude (Fig. 5H). The average and SD of QChi OD val-
ues for the first 12 plates performed were calculated and taken
into consideration to validate the following diagnostic plates. The
same was done for QClo values.
Antibody titers follow a classic immune response
pattern
To determine antibody responses accurately, we performed serum
titrations using RBD protein to assay the anti-SARS-CoV-2 IgM,
IgG, and IgA responses. In agreement with earlier results, not all
subjects assessed early (pre-day 7) after the onset of COVID-19 or
those asymptomatic show seroconversion, but anti-RBD antibod-
ies rise swiftly during the first days of infection. This is the case
for all three isotypes assessed. As with many reported antibody
responses, including SARS [15], the anti-SARS-CoV-2 response
follows a classic pattern with high antibody responses at the start
of the immune response (Supporting Information Fig. S3A–C).
In addition to early responses from healthcare workers and
hospitalized patients, we analyzed 209 potential plasma donors
for convalescent plasma therapy via the Portuguese Blood and
Transplantation Institute (IPST). The volunteers were predomi-
nantly male (67%) and on average 38 years old. All were reported
to be SARS-CoV-2 PCR positive, on average 107 days prior to
serum sample collection (Table 5). COVID-19 symptoms varied
from asymptomatic to mild and moderate. At the time of collec-
tion, 184/209 (88%) of the potential plasma donors had readily
detectable IgG anti-SARS-CoV-2 RBD antibodies. In line with a
characteristic immune response, antibody titers assessed in volun-
teers were reduced compared with titers found during the early
immune response in COVID19 patients and healthcare workers,
especially IgM and IgA (Supporting Information Fig. S3D–F).
Analysis of the IgM, total IgG, and IgA responses confirmed a
rapid and near-simultaneous response of the three isotypes tested
during the first weeks of SARS-CoV-2 infection (Fig. 6A–C).
Antibody responses peaked around three weeks after the first
symptoms, after which the circulating antibody levels were
reduced. IgM, IgG, and IgA peaked at days 15-21 with geometric
antibody titer means of 1915, 10695, and 5212, respectively.
From the second month after disease onset IgG and IgA antibody
levels remained readily detectable in most people up to 6 months
after first symptoms (Fig. 6A–C; Supporting Information Fig.
S3G). Characteristically for antibody response, IgM titers were
low (≤1/200) in 130 of 182 (72%) of IgG-positive potential
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plasma donors (Fig. 6A–C). Geometric means of IgM, IgG, and
IgA titers at days 91–120 were 96, 533, and 141, respectively.
Early anti-SARS-CoV-2 RBD antibody levels (day 40) were higher
in men, with significantly higher titers for all three antibody
isotypes, but at late time points (Day 40-150) no differences
between men and women were observed (Figure 6D-I). The
increased antibody level observed in men was not explained by
the severity of COVID-19, with the overall increase in antibod-
ies observed independently of disease symptoms (Supporting
Information Fig. S3H). Furthermore, stratifying subjects within
the first 40 days after COVID-19 by the severity of symptoms
highlighted that increased severity correlates well with increased
antibody titers at early stages (Fig. 6J–L).
Since titers 2 months after COVID-19 reduced, we next deter-
mined the antibodies’ potential to neutralize SARS-CoV-2. We
found neutralization activity in all tested sera in which anti-SARS-
CoV-2 IgG was determined, across 2–5 months after initial SARS-
CoV-2 PCR-positive testing (Fig. 6M). The level of SARS-CoV-2
neutralization activity was found to be proportional to the anti-
SARS-CoV-2 RBD IgG titer determined, but not IgM and only a
trend for IgA (Fig. 6N; Supporting Information Fig. S3I–J). Col-
lectively the data highlight that a sustained level of antibodies
circulate in the blood for at least 6 months after COVID-19, which
shows SARS-CoV-2 neutralizing activity in line with the level of
anti-SARS-CoV-2 RBD IgG titers.
Discussion
For many pathogens and vaccines, antibody titers have been
established over the past decades, accumulating detailed knowl-
edge of average antibody responses. However, every microorgan-
ism is different, and level, neutralization activity, and longevity of
antibody responses can be different between pathogens, vaccines
as well as between individuals. Therefore, it remains important
to acquire data for each novel infection, especially those posing a
threat to human health such as SARS-CoV-2. In addition, initial
antibody levels after vaccination, generally correlate well with a
significantly reduced risk of (re-)infection and pathology. Thus,
the global collection of data from many different geographic loca-
tions, patient cohorts, and under different local conditions will
contribute to a holistic understanding of the new pandemic.
We explain the setup of an ELISA system in detail, as described
previously [9], to facilitate implementation in other places and
comparison with published results. Although the Spike protein
used in the assay is not the only immune-reactive SARS-CoV-2
protein, it was selected because provides additional correlative
insights with respect to potential neutralizing antibodies present
[3, 4, 16]. The assay was set up using samples with high, medium,
and low titers, and an OD of 2.0 was selected to avoid saturating
signals. Although serum samples for the assay setup were deter-
mined with the initial assays prior to full optimization, this did
not affect their subsequent use.
We show that neither frequently used methods of viral inac-
tivation nor the complexity of RBD, monomeric, dimeric, or a
mixture of both affects antibody determination. Although the
reported presence of SARS-CoV-2 is limited in blood [17], the
inactivation of serum contributes to reduced risk handling human
material. Using the whole RBD fraction from mammalian expres-
sion systems will reduce costs due to its superior yield. The higher
levels of expression using the relatively small RBD, compared with
the full-length Spike protein, makes the use of RBD more econom-
ical. We show that individual samples can show differences in sig-
nal for either RBD or Spike and that some limited cross-reactivity
is observed with both proteins. However, there is no disadvantage
using RBD compared with the full-length Spike protein, result-
ing in high specificity and sensitivity. Care should be taken when
using serum samples from patients with increased antibody lev-
els. These can be observed in allergies and autoimmune condi-
tions, which may increase the background signal compared with
otherwise healthy controls. Most subjects who encountered SARS-
CoV-2 seroconverted, although some showed delayed kinetics.
Only a few patients did not show an IgG response that was not
explained by early sampling (<day 7) or an underlying condition
that required the use of immunosuppressive drugs. Most of the
non-responders were asymptomatic, which may point to a very
modest immune response upon encountering a low viral load, or,
since SARS-CoV-2 PCRs also generate false-positives, these partic-
ipants may not have been infected.
Within the patient cohort, there were additional groups of
interest. With SARS-CoV-2 being a positive-stranded RNA virus,
the use of anti-retroviral medication had no major effect on anti-
body responses against the virus. The mode of action of these
drugs is not known to interfere with RNA viruses or antibody pro-
duction. Our data show the successful management of the eleven
patients previously infected with HIV, with all of those patients
showing a robust SARS-CoV-2 antibody response after the second
week of COVID-19 symptoms, in line with previous works [18,
19]. The use of immunomodulatory drugs had an inhibitory effect
on SARS-CoV-2 seroconversion. This is in line with the action
mechanism of these drugs, inhibiting the activation or produc-
tion of lymphocytes. Although this will inhibit the clearance of
SARS-CoV-2, the use of these immune-inhibitory drugs such as
Dexamethasone could be beneficial in cases of severe immune
response against SARS-CoV-2, resulting in cytokine storm and
immunopathology [20].
We and others [4] found higher antibody titres in men com-
pared with women. This is surprising since women on average
have more B cells and produce more antibodies [21]. Higher anti-
body titres in men, only observed during the acute stage, corre-
lates well with men showing more severe symptoms and increased
fatality, as reported [22, 23]. Innate antiviral responses, such as
those mediated via toll-like receptor-7, are enhanced in women
[24], which may explain their increased resistance against SARS-
CoV-2, similarly to influenza virus [25].
In many countries implementing mitigation strategies, infec-
tion prevalence remained modest at the time of sampling,
May–June 2020, with a low frequency of infection [26–29]. This
increases the proportional contribution of any false positives to
the result. The ELISA assay as used was approved by the FDA
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Table 4. Demographics of patient participants under immunomodulatory or antiviral medication, disease severity categories and symptoms,
underlying conditions and medication
Clinical data (%, n) Immunomodulatory Antiviral
Age (years) 60.21 (20–87) 51.87 (43–60)
Male (%) 31% 9 100% 12
Female (%) 69% 20 0% 0
Sample collection date 6/4/2020 - 12/8/2020 6/4/2020 - 12/8/2020
SARS-CoV-2 PCR+ 100% 100%
Seroconversion (Spike) 28% (8/29) 75% (9/12)
Seroconversion (RBD) 31% (9/29) 75% (9/12)
Disease Severity
Asympomatic 24% 7 25% 3
Mild 14% 4 17% 2
Moderate 59% 17 58% 7
Severe 3% 1 0% 0
Symptoms
Cough 45% 13 0% 0
Myalgia 10% 3 17% 2
Fever 41% 12 58% 7
Anosmia 7% 2 0% 0
Dyspnea 31% 9 42% 5
Diarrhea 0% 0 17% 2
Odynophagia 0% 0 0% 0
Hypogeusia 0% 0 0% 0
Headache 7% 2 17% 2
Rhinorrhea 0% 0 0% 0
Asthenia 28% 8 8% 1
Days Post Symptom onset at collection 10.96 (2-35) 9.00 (3-11)
PCR+ day to serum collection 6.43 (1-13) 6.17 (1-11)
Underlying conditions
None 0.00% 0 0.00% 0
Chronic kidney disease 17.24% 5 25.00% 3
Diabetes 17.24% 5 16.67% 2
Hypertension 34.48% 10 16.67% 2
Heart disease 6.90% 2 0.00% 0
Alzheimer 0.00% 0 0.00% 0
Cerebrovascular disease 3.45% 1 0.00% 0
Dementia/Parkinson 17.24% 5 0.00% 0
Asthma 0.00% 0 0.00% 0
Cancer 37.93% 11 0.00% 0
COPD 0.00% 0 0.00% 0
HIV 0.00% 0 91.67% 11
SLE 6.90% 2 0.00% 0
Medication
None 0.00% 0 0.00% 0
Midostaurin 3.45% 1 0.00% 0
Aciclovir 3.45% 1 0.00% 0
Tacrolimus 17.24% 5 0.00% 0
Prednisolone 41.38% 12 0.00% 0
Chemotherapy (Paclitaxel) 6.90% 2 0.00% 0
Methotrexate 3.45% 1 0.00% 0
Raltegravir 0.00% 0 25.00% 3
Darunavir/Cobicistat 0.00% 0 25.00% 3
Exemestane 6.90% 2 0.00% 0
Azathioprine 10.34% 3 0.00% 0
Dexamethasone 3.45% 1 0.00% 0
Tamoxifen 6.90% 2 0.00% 0
(Continued)
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Table 4. Continued
Clinical data (%, n) Immunomodulatory Antiviral
Abacavir 0.00% 0 33.33% 4
Lamivudina 0.00% 0 33.33% 4
Micofenolate 6.90% 2 0.00% 0
Entecavir 0.00% 0 8.33% 1
Dolutegravir 0.00% 0 25.00% 3
as a two-step method (https://www.fda.gov/media/137029/
download). We show that using only one protein for a large
population screen picks up some false positives (30/2571; 1.2%).
Especially when the infection rate is low, the two-step method is
highly beneficial and strongly recommended [27]. Furthermore,
the introduction of an additional dilution step ensures robustness,
resulting in 1.5% (38/2571) of the staff members that serocon-
verted. Overall, there were limited differences between RBD and
Spike reactivity, with a few samples responding more robustly
to Spike, possibly reflecting the increased amount of epitopes
available in the larger protein.
The question of long-lasting and protective immunity against
SARS-CoV-2 is a focus of current research. We show that the
initial antibody response against SARS-CoV-2 raises the three
main isotypes in close concert as previously reported for SARS as
well as SARS-CoV-2 [15, 30]. The kinetics of the response follows
Figure 5. Largescale seroconversion testing of Lisbon University staff. SARS-CoV-2 IgG antibody detection in 1/50 diluted serum samples from
University of Lisbon staff using Immulon 4HBX 96-well plates for ELISA. Absorbance was evaluated at 450 nm. (A) Schedule of screening plates,
coated with 2 μg/ml RBD, accommodating 90 samples/plate, and includes two blanks, two quality control at high concentration (QChi), and two at
low concentration (QClo). B) Overview of tested staff from Lisbon University (n = 2571 donors). Red symbols indicate negative scores, purple symbols
indicate ODs above the cutoff. (C) Schedule of re-screening plates, coated with 2 μg/ml RBD (left) or Spike (right), accommodating 21 samples/plate,
and includes two dilutions per sample (1/50 and 1/150), two blanks, two QChi, and two QClo per protein used. (D) Screening results from the re-
screen (n = 68 donors), showing samples tested on Spike protein. Green depicts those samples above the cut off for RBD and Spike at both 1/50 and
1/150 dilution (n = 38); Red indicates those samples below the cut off on the second screen for either RBD or Spike (n = 30). (E–G) Showing RBD and
Spike protein signals for the re-assessed samples and an additional 10 negative samples, (E) all samples, (F) samples assessed negative (open to
red symbols) and an additional 10 that were originally negative (red to red symbols), (G) samples assessed as positive (open to green symbols). (H)
Quality control signals for 12 sequential plates, showing QChi (circles) and QClo (squares). Dotted lines indicate average signal ± SD for QChi (red,
200ng/ml) and QClo (blue (10 ng/ml)) of human anti-SARS-CoV-2. Data show individual sample values.
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Table 5. Demographics of potential plasma donor participants and
determined IgG titres
Potential plasma donors
Age (years) 37.91 (18-58)
Male (%) 67% 139
Female (%) 33% 70
Sample collection date 8/6/2020 - 30/9/2020
SARS-COV2 PCR+ 100%
Seroconversion (RBD) 88% (184/209)
PCR+ day to serum collection 107 (47-199)
PCR- day to serum collection 81 (15-183)
Titer IgG n %
No titer 23 11%
Low (50–300) 31 15%
Medium (300–900) 135 65%
High (>900) 20 10%
a well-known pattern with antibody levels peaking around 3
weeks after symptoms and declining thereafter. Late responses
are characterized by low or sometimes undetecTable levels of
IgM, modest IgA, but at least until 199 days post-PCR-positive
reaction, mostly a robust IgG response. Between days 40 and 199,
we found 90% of previous SARS-CoV-2-PCR-positive subjects
(198/221), healthcare workers, and potential plasma donors,
to carry antibodies, 75% of which had medium to high titers
(>300). In addition, we found that in subjects with detectable
anti-SARS-CoV-2 IgG, neutralization activity was in accordance
with the determined IgG titer level. This is in agreement with a
recent report [16]. This and the strong correlation between RBD
IgG titers and neutralizing activity as well as protective immunity
[16, 31], suggests that most people infected with SARS-CoV-2
will have circulating protective immunity for many months after
COVID-19. In addition, recent reports of T cell responsiveness
[32–35] show a robust T cell response. Since the SARS-CoV-2
response is in line with well-known and detailed studied immune
responses resulting in lymphocyte memory, it is very likely that
SARS-CoV-2 protective immunity, reducing disease severity, will
last for at least a few years.
Materials and methods
SARS-CoV-2 RBD and Spike protein constructs
RBD and Spike protein constructs were obtained from Dr. Florian
Krammer, Icahn School of Medicine at Mount Sinai, New York,
USA.
Production and purification of antigen recombinant
proteins
Production and purification of recombinant proteins were per-
formed at Instituto de Biologia Experimental e Tecnológica (iBET)
Oeiras, Portugal as part of the Serology4COVID consortium as
previously described by Stadlbauer et al. [12]. Briefly, Spike or
RBD antigen containing His-tag is produced by transient trans-
fection of Expi293FTM cells (Thermo Fisher Scientific) with plas-
mids suitable for mammalian cell expression (pCAGGS), harbor-
ing Spike gene or RBD gene, respectively. All purification steps
were performed at 4°C. At 3 days post-transfection, cultures are
centrifuged and supernatants are collected and filtered through
Sartopore MidiCaps. The clarified supernatants are concentrated
and dialyzed with binding buffer by tangential flow filtration,
using 10 kDa or 30 kDa membranes, for RBD or Spike purifi-
cation, respectively. The final dialyzed and concentrated sample
is filtered through a 0.22 μm membrane and loaded into His-
Trap HP columns, equilibrated with binding buffer. Proteins are
eluted with a linear gradient up to 500 mM Imidazole. The frac-
tions containing Spike or RBD are concentrated to 1–2 mg/ml
using Vivaflow 200 crossflow devices. Removal of imidazole and
exchange to PBS buffer is performed by diafiltration with 10 vol-
umes of PBS. Protein concentration is determined by A280nm
combined with the specific extinction coefficient. The concen-
trated and formulated products are filtered through 0.22 μm
membrane, aliquoted, snap-frozen in liquid nitrogen, and stored
at -80°C.
Human samples collection
Upon informed consent, blood was taken by vein puncture
and two BD Vacutainer CPT tubes of blood and one serum
tube were collected per patient. For serum collection, tubes
were centrifuged at 2200 rpm, 10 min at 4oC, and upper 6 ×
0.25 ml of serum placed into six cryotubes. Samples are stored
in a temperature-controlled -80oC ultra-low freezer at the iMM
Biobank until analysis.
Serum samples were obtained from the iMM biobank COVID-
19 collection and pre-pandemic control sera from two allergy
collections. Patients were recruited from the COVID-19 unit and
the Immunoallergology Department of Hospital de Santa Maria,
Centro Hospitalar Lisboa Norte. The COVID-19 collection and
scientific use were approved by the Lisbon Academic Medical
Center Ethics Committee (Ref. no. 155/20) as was the staff
screening (Ref. no. 181/20). The allergy studies were approved
with reference 116/13. Potential plasma donors registered vol-
untarily via the IPST website. Criteria for registration were a
diagnosis of COVID-19 documented by a positive PCR test for
SARS-CoV2 followed by two negative or one negative PCR tests
14 or 28 days prior to collection, respectively. Medical interviews
were conducted to ensure that the criteria for apheresis plasma
donation were fulfilled and that a full recovery from COVID-19
had been achieved.
Signed informed consent was obtained from all volunteers.
All data were treated confidentially and anonymous, according
to (EU) 2016/679 of 27 April 2016 (General Data Protection Reg-
ulation). A professional obliged to confidentiality with guarantee
appropriate information security measures carried out the data
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Figure 6. Longitudinal SARS-CoV-2 antibody titers. SARS-CoV-2 antibodies were assessed in 1/50 diluted serum samples from donors in Portugal
using Immulon 4HBX 96-well plates for ELISA. Absorbance was evaluated at 450 nm. (A–C) Anti-SARS-CoV-2 RBD antibody titers plotted over time
for (A) IgM, (B) IgG, and (C) IgA (n = 356 total donors). Red line marks the geometric mean. (D–I) Anti-SARS-CoV-2 antibody titers for males and
females during (D, F, and H) early, days 7–40 (females n = 32, males n = 29) or (E, G, and H) late response, days 40–150 (females n = 60, males n = 114)
for (D and E) IgM, (F and G) IgG or (H and I) IgA. Red line marks the mean. (J–L) Anti-SARS-CoV-2 RBD antibody titers plotted by severity of COVID-19
symptoms experienced for (J) IgM, (K) IgG, and (L) IgA. Red line indicates the mean (Asymptomatic n = 13, Mild n = 28, moderate n = 54, severe n =
8). (M and N) SARS-CoV-2 neutralizing activity was determined in sera (n = 84 total donors) and plotted against (M) time since SARS-CoV-2 PCR+ or
N) IgG titer. Red lines indicate geographic mean. Statistical analysis was performed using Mann–Whitney U-test (d–i) or Kruskal–Wallis test using
Graphpad Prism software. *p < 0.05, **p < 0.01, ***p < 0.001. Data show individual sample values.
collection under the terms of the GDPR paragraph 2, article 29
Law no. 58 /2019, 8 August.
Virus inactivation
To reduce risk from any potential residual virus in the serum,
three different virus inactivation methods were tested: incubation
for 1 h at 56°C (heat inactivation), the addition of 0.1% Triton X-
100 (a non-ionic surfactant), or the combination of both (H+ Tx).
Antibody measurements
Anti-SARS-CoV-2 ELISAs were performed as described previ-
ously [12]. Briefly, flat-bottom 96-well plates (Immulon 4 HBX;
Thermo Scientific) were coated with recombinant protein RBD
or Spike prepared in PBS at a concentration of 2 μg/ml
(50 μl/well) overnight at 4°C. Coated plates were washed with
PBS-0.05%Tween (PBS-T) using a Well-wash 1x8 (Thermo Fisher
Scientific) or Aquamax200, 3× for IgG detection, and 10×
for IgM analysis. Plates were blocked with 200 μl/well of 3%
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non-fat milk powder in PBS-1%T for 1 h at room temperature
and then washed with PBS-T 3× or 10×, as described previ-
ously. Serum samples were diluted in PBS-0.1%T + 1% non-
fat milk powder, added (100 μl/well) and incubated for 1–2 h
at room temperature, washed with PBS-T 3× or 10×. Hereafter
several antibody isotypes, namely Total Ig, IgG, IgM, and IgA anti-
SARS-CoV2 were detected using HRP-labeled goat anti-human
IgG+IgM+IgA (Abcam, ab102420), IgG Fc (Abcam, ab97225),
IgM mu chain (Abcam, ab97205), IgA alpha chain (Abcam,
ab97215), respectively. Secondary antibodies were diluted in PBS-
0.1%T + 1% non-fat milk powder (50 μl/well) and added for 1 h
at room temperature, washed with PBS-T 3× or 10×, and devel-
oped with TMB substrate solution (TMB Substrate Reagent Set,
BD OptEIATM, 555214), 100 μl/well for 10 min. The reaction was
stopped with 1M sulphuric acid (50 μl/well) and OD at 450nm
was measured via Infinite M200 (TECAN) plate reader. Each plate
contained a Quality control (QC) sample, composed of a pool of
positive samples or monoclonal antibody, tested in a high and low
dilution. For material details, see Methods supplement.
Neutralization assays
Anti-SARS-CoV-2 ELISAs were performed as described in detail
recently [36]. SARS-CoV-2 pseudo particles (pp) were kindly pro-
vided by Dr Benhur Lee, Icahn School of Medicine at Mount Sinai,
New York, USA. Briefly, 24 h prior to infection, Vero CCL81 cells
grown in DMEM supplemented with 10% FBS were seeded at
20 000 per well in a 96-well plate. SARS-CoV-2pp and serial dilu-
tions of sera ( 1/10 in DMEM with 10% FBS, and further twofold
dilutions) were incubated at room temperature for 30 min. Media
from Vero cells was substituted with the SARS-CoV-2pp/serum
mix; plates were spinoculated by centrifugation at 1250 rpm for
1 h at 37°C. After overnight incubation at 37°C, culture medium
was removed, and Renilla luciferase production was assessed on
Tecan 2 plate reader using the Dual-luciferase Reporter Assay
system (Promega), according to manufacturer instructions. IC50
were determined as the last serum dilution at which the titration
curve matches inhibition equal or above 50% of the 100% assay.
Statistical analyses
A Kruskal–Wallis test (non-parametric test) was done to compare
the geometric ratios between groups with a significance level of
0.05 (Dunn’s multiple comparisons test), Student’s t-test or two-
way ANOVA were used as stated in the figure legends, calculated
using GraphPad Prism 6.0 software.
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